Previous 10 | Next 10 |
C4 Therapeutics, Inc. ( NASDAQ: CCCC ) added ~7% pre-market Thursday after the clinical-stage biotech announced that the FDA issued a Study May Proceed Letter to start a Phase 1/2 trial for its oral solid tumor candidate CFT1946. CFT1946 is designed to target the BRAF-...
WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treate...
WATERTOWN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treate...
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
C4 Therapeutics press release ( NASDAQ: CCCC ): Q2 GAAP EPS of -$0.56 beats by $0.12 . Revenue of $13.84M (+41.2% Y/Y) beats by $5.33M . For further details see: C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical Trial for CFT8634, a BRD9 Degrader, Enrolling Patients and Progressing Through Phase 1 Dose Escalation – ...
– Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches – – Dr. Donna Grogan Joins as Accomplished Drug Development and Regulatory Strategy Leader With Mor...
Gainers: Inter & ( INTR ) +34% . Cytokinetics ( CYTK ) +6% . MSP Recovery ( MSPR ) +6% . Ocular Therapeutix ( OCUL ) +5% . Kirkland's ( KIRK ) +5% . Losers: Microvast Holdings ( MVST ) -7% . Virgin O...
Gainers: DBV Technologies (DBVT) +48%. Biodesix (BDSX) +15%. Intel Corporation (INTC) +7%. Limoneira (LMNR) +6%. Groupon (GRPN) +5%. Losers: Redbox Entertainment (RDBX) -5%. C4 Therapeutics (CCCC) -5%. Kezar Life Sciences (KZR) -5%. Iris Energy Limited (IREN) -5%. LumiraDx Lim...
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated,...
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...